New approaches in the treatment of bacterial infections

Current Opinion in Chemical Biology

Volumn 4, Issue 4, 2000, Pages 433-439

  Bush, Karen ^a   Macielag, Mark ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMIDE; ANTIINFECTIVE AGENT; BAMBERMYCIN; BPI R 21; CARBOHYDRATE; CETHROMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIPEPTIDE; GATIFLOXACIN; GEMIFLOXACIN; GLYCOPEPTIDE; IB 367; KETOLIDE; LINEZOLID; LIPID; MOXIFLOXACIN; NISIN; OXAZOLIDINE DERIVATIVE; PEPTIDE; PNU 100480; PROTEGRIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RBPI 21; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; ENTEROCOCCUS FAECIUM; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HEMOLYTIC STREPTOCOCCUS; HUMAN; LACTOBACILLUS; LEUCONOSTOC; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOBACTERIUM; NEISSERIA; NONHUMAN; PEDIOCOCCUS; PENICILLIN RESISTANCE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES;

EID: 0033863667     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00106-X     Document Type: Review

References (60)

1. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal
2. First drug for penicillin-resistant community-acquired pneumonia
3. Quinupristin/dalfopristin: A review of its use in the management of serious Gram-positive infections
4. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
5. Phenotypic distinction in Enterococcus faecium and Enterococcus faecalis strains between susceptibility and resistance to growth-enhancing antibiotics
6. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci
7. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium
8. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
9. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones
10. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group
11. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
12. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
13. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci
14. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
15. Oxazolidinones: A review
16. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
17. Serum inhibitory titers and serum bactericidal titers of human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid
18. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections
19. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteria with linezolid and gentamicin
20. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
21. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis
22. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
23. Development of linezolid-resistant Enterococcus faecium in two Compassionate Use Program patients treated with linezolid
24. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis
25. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
26. New antibiotics in development in the macrolide, lincosamide and streptogramin group
27. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria
28. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin-resistant and susceptible pathogens
29. In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-hemolytic streptococci
30. In vitro activities of ketolides HMR3647 and HMR 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis
31. In vitro activities of ketolide HMR3647, macrolides, and other antibiotics against Lactobacillus, Leuconostoc, and Pediococcus isolates
32. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology
33. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes
34. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials
35. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
36. Host defence (cationic) peptides: What is their future clinical potential?
37. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters
38. The lantabiotic nisin, a special case or not?
39. Use of the cell wall precursor Lipid II by a poreforming antibiotic
40. Antibiotics: Non-haemolytic beta-amino-acid oligomers
41. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
42. Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens
43. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936
44. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
45. In vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
46. Genomics and antimicrobial drug discovery
47. Carbohydroxamido-oxazolidines: Antibacterial agents that target lipid A biosynthesis
48. Anchor structure of staphylococcal surface proteins. IV. Inhibitors of the cell wall sorting reaction
49. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall
50. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor
51. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa
52. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin
53. Role in cell permeability of an essential two-component system in Staphylococcus aureus
54. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae
55. Novel streptopyrroles from Streptomyces rimosus with bacterial protein histidine kinase inhibitory and antimicrobial activities
56. Use of combinatorial library screening to identify inhibitors of a bacterial two-component signal transduction kinase
57. 6-Oxa isosteres of anacardic acids as potent inhibitors of bacterial histidine protein kinase (HPK)-mediated two-component regulatory systems
58. Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems
59. Drug target validation: Lethal infection blocked by inducible peptide
60. Harnessing the power of the genome in the search for new antibiotics